SAN DIEGO , Aug. 24, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced a new collaboration with Fresenius Kidney Care to provide the most accurate* COVID-19 self-test to certain patients and clinical care teams.
People who are immunocompromised have been disproportionately affected by COVID-19 throughout the pandemic and remain highly dependent on measures that reduce the likelihood of infections, including vaccination. Cue can be used by vulnerable patient populations and their care partners to detect and treat COVID-19 early, often before complications arise and hospitalization is required. This is especially important in remote locations where timely and accurate results are critical for making clinical treatment decisions. Fresenius Kidney Care in Hawaii , Alaska , Puerto Rico , Guam , and Saipan will use the Cue Health Monitoring System and Cue COVID-19 Test to screen employees and test symptomatic immunocompromised patients in-center and at-home.
"This is a great example of how Fresenius Kidney Care is seeking out the best technologies to ensure we do everything we can to protect our vulnerable patient population from COVID-19," said Ines Dahne-Steuber , President of Spectra Laboratories, a Fresenius Medical Care company providing laboratory diagnostics to dialysis centers across the country. "This collaboration with Cue will help us provide patients with greater access to high-quality timely diagnosis and care in our effort to improve health outcomes while lowering costs."
Fresenius Kidney Care operates more than 2,600 dialysis centers in the U.S., providing more than 200,000 patients annually with services that include at-home peritoneal dialysis, at-home hemodialysis, in-center hemodialysis, and additional clinical care resources.
"By utilizing Cue's platform, Fresenius Kidney Care can continue to provide its life-saving services to immunocompromised patients with confidence they are using the most accurate COVID-19 self-test," said Ayub Khattak , Chairman and CEO of Cue Health. "We treat accuracy as non-negotiable so healthcare-affiliated organizations across the country can continue to trust Cue for their testing needs in high-stakes environments."
Fresenius Kidney Care is one of the growing number of healthcare-affiliated organizations and internationally-recognized hospital systems throughout the U.S working with Cue to transform how diagnostic healthcare is delivered to close gaps in the patient journey and drive improved health outcomes. Cue is used in many other point-of-care settings such as Johns Hopkins Medicine and Mayo Clinic, by world-class organizations across the country, including Google, the National Basketball Association, and Major League Baseball, and in homes.
Cue's test uses molecular nucleic acid amplification technology (NAAT) providing lab-quality results directly to connected mobile devices in 20 minutes. The test can detect all known COVID-19 variants and subvariants of concern - including Omicron, BA.4, and BA.5 - and can be used on adults and children (age 2 years and over for over-the-counter (OTC) / home use and under 2 for professional use), with or without symptoms.
*Based on clinical study results submitted to FDA for other EUA molecular home tests.
About Cue Health Cue Health ( Nasdaq: HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care. Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. Outside the United States , Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore's Health Sciences Authority. Cue was founded in 2010 and is headquartered in San Diego . For more information, please visit www.cuehealth.com.
Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements". The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those related to the expected future diagnostic test menu and the factors discussed in the "Risk Factors" section of Cue's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 10, 2022 . Any forward-looking statements contained in this press release are based on the current expectations of Cue's management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
These products have not been FDA cleared or approved; but have been authorized by FDA under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cue-health-provides-enhanced-care--protection-for-immunocompromised-populations--clinical-care-teams-at-fresenius-kidney-care-301611012.html
The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological treatment, and shares crashed.
Shares of Dollar Tree Inc. fell 1.0% in afternoon trading Friday, and the Canada-listed shares of Dollarama Inc. slipped 0.4%, after Canada's Environment Defence announced this week
A former ShorePoint Health Venice employee filed the lawsuit Aug. 29 — on behalf of herself and approximately 600 other employees — alleging CHS and the hospital violated the Worker Adjustment and Retraining Notification Act.
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Exebacase Active in Rabbit Model of MRSA Implant-Associated Osteomyelitis On July 15, 2022, ContraFect Corp. (NASDAQ:CFRX) announced the publication of results in the Journal of Bone and Joint Infection from a preclinical rabbit model of implant-associated methicillin-resistant Staphylococcus aureus (MRSA)
The patent is expected to provide the company with exclusivity for its experimental RNAi therapeutic until at least April 2038.
The "Grace & Frankie" star said she won't let her cancer treatments stand in the way of her climate activism.
The vegetable was shown to lower blood sugar levels and cholesterol levels
The Centers for Disease Control and Prevention recommended Thursday that teenagers and adults get updated booster shots from Pfizer or Moderna.
Two years after raising $277 million in its IPO, a Watertown biotech developing drugs for blood diseases is being acquired by Novo Nordisk.
The latest booster shots, which health authorities have been counting on to protect people once the weather turns colder and cases often rise, will be widely available in the coming days.
If you’re old enough to have a child, you’re old enough to decide that you don’t want them. Each year, around 700,000 child-bearing people choose to be sterilized, and that number is only growing following the fall of Roe v. Wade. After the Supreme Court took away our constitutional right to abortion healthcare, the search volume for terms such as “tubes tied” and “tubal litigation,” the process by which the fallopian tubes are blocked or cut, nearly quadrupled. These procedures have always been
Nearly 100 people have gotten sick.
Hesitant parents and challenging logistics are slowing the effort to get the nation’s youngest protected against Covid-19.
A smoked salmon product sold in 10 states is being recalled after a sample tested positive for Listeria. The recall concerns 4-oz. packages of St.
Many people don't realize that the term "abortion" covers a vast variety of procedures in countless different circumstances.
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
The updated shots, designed to work against the current variations of Covid-19, come as people return to schools and offices and holidays approach.
The Oklahoma Health Department preordered supplies of the updated COVID-19 vaccines, which could arrive in the state as soon as Tuesday.
Novel psychoactive chemicals with names like 2C-B, AMT and 5-MeO-DMT are freely available at online marketplaces and digital currencies help facilitate global trade.
Global conference to focus on advancing the life-saving impacts of genomic health care